Gilead Sciences, Inc. (GILD)

From the record

Gilead Sciences, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Gilead Sciences, Inc.'s 10 filed years say what it did: revenue went from $30 billion in fiscal 2016 to $29 billion in fiscal 2025, down 0.4% a year; it rose in 5 of 9 years; the deepest fall was 27% from fiscal 2016 to fiscal 2018; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Gilead Sciences, Inc.'s diluted share count shrank about 0.2% a year, and dividends and buybacks returned about 55% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 86 sales (85 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-09 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Gilead Sciences, Inc. earned about 38 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 39 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 62 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

Gilead Sciences, Inc.'s standing among 102 graded names in its industry family: revenue of $29 billion in fiscal 2025 ranks in the top 1% by size; a net margin of 28.9% ranks in the top 9%; revenue growth of 2.6% a year over the last 3 filed years ranks in the bottom 48% (its annual reports).

From the record

Gilead Sciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is O'Day, Daniel Patrick (Chairman & CEO, as filed), filing under that title since 2019-03-01, 7.7 years (top 22% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 6.6 years (top 26%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 45%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Gilead Sciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $7.6 billion against debt of $22 billion leaves -24.7% of its assets as net cash, bottom 3% of its family; cash from operations less capital spending is 32.1% of revenue (top 7%); a gross margin of 78.8% (top 35%); research spending of 19.7% of revenue (bottom 16%) (its annual report).

From the record

Gilead Sciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.6% a year over the last three filed years against -0.4% over all 10, speeding up (top 25% of its family); the newest year grew 2.4% (bottom 39%); research spending grew 5.2% a year (top 44%); capital spending grew -8.2% a year (top 29%) (its annual reports). Gilead Sciences, Inc. reported 13 product lines in fiscal 2025: HIV Products Biktarvy at $14 billion (49%), Oncology Product at $3.2 billion (11%), Cell Therapy Products Total Cell Therapy Product Sales at $1.8 billion (6%), and 10 more; 5 of 13 grew against the year before (its annual report).

From the record

Gilead Sciences, Inc.'s newest year against its own record: revenue of $29 billion in fiscal 2025 came in 0.3% below the $30 billion its prior three years' pace pointed to (bottom 49% of its family); net income of $8.5 billion against a prior three-year average of $3.6 billion (top 12%); a net margin of 28.9% against 13.1% before (bottom 45%) (its annual reports).